Evidence-based·Updated November 19, 2026·How we grade evidence

Cagrilintide (CagriSema)

PeptideInvestigational weight-loss drug (not FDA-approved)

CagriSema combines the investigational amylin drug cagrilintide with the approved drug semaglutide. In the main 68-week phase 3 trial, adults with obesity lost on average 20.4% of their body weight, compared with 3.0% on placebo, and in an East Asian trial it beat semaglutide alone by 6.5 percentage points. It also lowered blood sugar in type 2 diabetes. Neither CagriSema nor cagrilintide is FDA-approved, and heart outcome results are not yet available.

Taking Cagrilintide (CagriSema) with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with obesity or type 2 diabetes who qualify for and choose to join a registered clinical trial; everyone else can ask a doctor about approved options, which include semaglutide on its own

Common dosing range

No approved dose. Phase 3 trials mainly studied cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly, and lower levels of 1.7 mg or 1.0 mg of each

When to expect effects

The dose was raised over 8 to 16 weeks; weight loss was measured at 68 weeks and blood sugar at 40 to 68 weeks

Watch out for

Not FDA-approved and cannot be prescribed outside a trial. FDA says cagrilintide cannot be used in compounding and is not a component of any FDA-approved drug, so products sold online are unapproved and unverified. Stomach side effects affected about 3 in 4 people in the main trials

What is it

Cagrilintide is an investigational drug that is not FDA-approved for any use, alone or in CagriSema, its once-weekly combination with semaglutide, so neither can be prescribed outside a clinical trial, and any product sold now as cagrilintide (including vials labeled "for research use only") is unapproved and unverified. FDA says cagrilintide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Cagrilintide is a long-acting version of amylin, a hormone released by the pancreas with insulin. Its developer, Novo Nordisk, has published phase 3 trials of CagriSema in adults with obesity and in type 2 diabetes in 2025 and 2026; a heart outcomes trial (REDEFINE 3), trials in children and adolescents, and phase 3 trials of cagrilintide on its own (the RENEW trials) are still running on ClinicalTrials.gov. Semaglutide, the other half of CagriSema, is an approved drug (Ozempic, Wegovy), but the combination is not.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You meet the entry criteria of a registered CagriSema or cagrilintide trial (listed on ClinicalTrials.gov) and decide with the study team that you want to take part
You would rather wait to see whether FDA approves it and, meanwhile, discuss approved weight-loss or diabetes medicines with a prescriber
You have tried semaglutide with a prescriber and want to follow, with your doctor, how the combination compares in trials

Probably skip if…

You would be buying cagrilintide online, from a telehealth service, a compounding pharmacy or a "research peptide" seller, or mixing it with semaglutide yourself: FDA says cagrilintide cannot be used in compounding, and warns that illegally marketed GLP-1 drugs sold online may be counterfeit or contain the wrong ingredients or amounts
You have a personal or family history of medullary thyroid cancer or MEN 2: this is a contraindication for semaglutide, half of the combination
You are pregnant, trying to become pregnant or breastfeeding
You expect proven heart benefits: the heart outcomes trial of CagriSema has not reported

Evidence at a glance

weight loss in adults with obesity without diabetes

Good Evidence
Effect
17.3 percentage points more weight loss than placebo at 68 weeks (REDEFINE 1); 6.5 percentage points more than semaglutide alone (REDEFINE 5)
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Time
Measured at 68 weeks

weight loss in adults with type 2 diabetes

Good Evidence
Effect
10.4 percentage points more weight loss than placebo at 68 weeks
Best fit
Adults with type 2 diabetes and a BMI of 27 or more
Time
Measured at 68 weeks

blood sugar (HbA1c) in type 2 diabetes

Good Evidence
Effect
HbA1c 1.7 percentage points lower than placebo (REIMAGINE 1); 0.16 points lower than semaglutide alone (REIMAGINE 2)
Best fit
Adults with type 2 diabetes, including those on metformin or basal insulin
Time
Measured at 40 to 68 weeks

weight loss with cagrilintide alone

Limited Evidence
Effect
3.0 to 7.8 percentage points more weight loss than placebo at 26 weeks
Best fit
Adults with obesity without diabetes
Time
Measured at 26 weeks

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

weight loss in adults with obesity without diabetes

Disease adjunct
Good Evidence

In REDEFINE 1, a 68-week phase 3 trial of 3417 adults with obesity, or overweight with a weight-related condition, and without diabetes, CagriSema (2.4 mg of each drug weekly) lowered body weight by an average of 20.4%, compared with 3.0% on placebo. In REDEFINE 5, 331 adults in Japan and Taiwan (24% with type 2 diabetes) lost 18.4% on CagriSema, compared with 11.9% on semaglutide alone (also estimated as if treatment was taken as intended). In REDEFINE 9, 309 adults on the lower levels of 1.7 mg or 1.0 mg of each drug lost 20.7% and 21.0%, compared with 2.0% on placebo, estimated as if everyone had stayed on treatment. All trials were funded by Novo Nordisk. They did not test heart attacks, strokes or deaths, and the published results do not cover what happens after stopping.

Effect size
17.3 percentage points more weight loss than placebo at 68 weeks (REDEFINE 1); 6.5 percentage points more than semaglutide alone (REDEFINE 5)
Time to effect
Measured at 68 weeks
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Less likely
People with type 2 diabetes, who lost less weight in REDEFINE 2; people under 18, who are still being studied

Bottom line: Larger average weight loss than semaglutide alone in a head-to-head trial; no heart outcome data yet.

weight loss in adults with type 2 diabetes

Disease adjunct
Good Evidence

In REDEFINE 2, a 68-week phase 3 trial in 12 countries, 1206 adults with type 2 diabetes (HbA1c 7% to 10%) and a BMI of 27 or more received CagriSema (2.4 mg of each weekly) or placebo with lifestyle advice. Body weight fell by 13.7% on CagriSema and 3.4% on placebo, and 73.5% reached an HbA1c of 6.5% or less, compared with 15.9% on placebo. The trial was funded by Novo Nordisk and did not test diabetes complications or heart outcomes.

Effect size
10.4 percentage points more weight loss than placebo at 68 weeks
Time to effect
Measured at 68 weeks
Best fit
Adults with type 2 diabetes and a BMI of 27 or more
Less likely
People with type 1 diabetes, who were not studied

Bottom line: Meaningful weight loss in type 2 diabetes, though smaller than in people without diabetes.

blood sugar (HbA1c) in type 2 diabetes

Biomarker support
Good Evidence

In three phase 3 trials, CagriSema lowered HbA1c in adults with type 2 diabetes. In REIMAGINE 2 (2713 adults on metformin with or without an SGLT2 inhibitor, 68 weeks), HbA1c fell by 1.91 percentage points with 2.4 mg of each drug, compared with 1.75 with semaglutide 2.4 mg alone, a small but statistically significant difference. In REIMAGINE 1 (189 adults on diet and exercise, 40 weeks), it fell by 1.8 points, compared with 0.1 on placebo. In REIMAGINE 3 (274 adults on basal insulin, 40 weeks), it fell by 2.33 points, compared with 0.66 on placebo, with no severe low blood sugar reported. All were funded by Novo Nordisk.

Effect size
HbA1c 1.7 percentage points lower than placebo (REIMAGINE 1); 0.16 points lower than semaglutide alone (REIMAGINE 2)
Time to effect
Measured at 40 to 68 weeks
Best fit
Adults with type 2 diabetes, including those on metformin or basal insulin
Less likely
Children and adolescents, who are still being studied

Bottom line: It lowers blood sugar well, but only slightly more than semaglutide alone.

weight loss with cagrilintide alone

Disease adjunct
Limited Evidence

In a 26-week phase 2 trial in ten countries, 706 adults with obesity, or overweight with high blood pressure or abnormal blood fats, and without diabetes were assigned to cagrilintide 0.3 to 4.5 mg weekly, liraglutide 3.0 mg daily or placebo. Weight fell by 6.0% to 10.8% depending on dose, compared with 3.0% on placebo, and the 4.5 mg dose produced more weight loss than liraglutide 3.0 mg daily (10.8% vs 9.0%). The trial was funded by Novo Nordisk and was short. Phase 3 trials of cagrilintide on its own (RENEW 1, 2 and 4) are still running.

Effect size
3.0 to 7.8 percentage points more weight loss than placebo at 26 weeks
Time to effect
Measured at 26 weeks
Best fit
Adults with obesity without diabetes
Less likely
Anyone expecting the larger losses seen with the combination

Bottom line: On its own, cagrilintide caused moderate weight loss in one short phase 2 trial.

How it works

Amylin is a hormone that the pancreas releases together with insulin after a meal. It signals fullness to the brain, slows stomach emptying and lowers the release of glucagon, a hormone that raises blood sugar. Natural amylin lasts only minutes in the body; cagrilintide was designed to last long enough for a once-weekly injection. Semaglutide acts on a different hormone receptor, GLP-1, which also reduces appetite and helps insulin release. CagriSema gives both drugs together once a week by injection under the skin, with the idea that two separate fullness signals add up. In a head-to-head trial in Japan and Taiwan, the combination produced more weight loss than semaglutide alone.

How to take it

1. Typical dose
There is no approved dose. In the main phase 3 trials, participants received cagrilintide 2.4 mg plus semaglutide 2.4 mg injected under the skin once a week; in REDEFINE 1 this followed a 16-week step-up period. In REDEFINE 9, participants received 1.7 mg of each (raised over 12 weeks) or 1.0 mg of each (raised over 8 weeks), both starting at 0.25 mg of each. These are studied doses, not recommendations; in a trial the study team sets the dose.
2. Higher studied dose
Cagrilintide on its own was studied at 0.3 to 4.5 mg once weekly in a 26-week phase 2 trial. The combination's phase 3 trials used at most 2.4 mg of each drug.
3. Timing
Once a week by injection under the skin in trials
4. With food
Food instructions have not been established for this investigational drug
5. Split dosing
Not studied; trials used one weekly injection
6. How long to try
Phase 3 trials lasted 40 to 68 weeks of treatment. Longer trials are running, and no results after stopping have been published in the trial reports listed here

What to track

In a trial, the study visits and blood tests the study team schedules
Nausea, vomiting, diarrhea, constipation or stomach pain, and signs of dehydration
Severe stomach pain that does not go away, with or without vomiting (a warning sign of pancreatitis on the semaglutide label): get urgent care
Low blood sugar symptoms if you also take insulin or a sulfonylurea
Pain in the upper right belly, fever or yellow skin (gallbladder problems are a warning on the semaglutide label)

Bottom line: Strong weight loss in trials, but an unapproved combination: a registered clinical trial is the only legitimate way to receive it now.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Nausea, vomiting, diarrhea, constipation or stomach pain (79.6% on CagriSema vs 39.9% on placebo in REDEFINE 1; 72.5% vs 34.4% in REDEFINE 2), mostly mild to moderate and temporaryInjection-site (administration-site) reactions, among the most frequent events with cagrilintide alone in phase 2

Serious risks

  • Boxed warning on the semaglutide label, which applies to the semaglutide in CagriSema: semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether it causes medullary thyroid cancer in people. It must not be used with a personal or family history of medullary thyroid cancer or MEN 2.

  • Other warnings on the semaglutide label, which apply to the semaglutide in CagriSema: pancreatitis, gallbladder disease, dehydration leading to kidney injury, low blood sugar with insulin or a sulfonylurea, severe stomach side effects (not recommended with severe gastroparesis), serious allergic reactions, worsening of diabetic eye disease (retinopathy) in people with type 2 diabetes, a faster heart rate, and food entering the lungs during anesthesia or deep sedation. Whether adding cagrilintide changes these risks is not established.

  • Stopping treatment. In REDEFINE 5, 10% stopped CagriSema, compared with 6% who stopped semaglutide alone. In the phase 2 trial of cagrilintide alone, 10% stopped treatment permanently, at similar rates across groups, and 4% stopped because of adverse events.

  • Unknown long-term and heart safety. The heart outcomes trial of CagriSema (REDEFINE 3, about 7100 adults with heart disease) is still running, with its primary completion estimated on ClinicalTrials.gov as September 2027.

  • Unapproved products of unknown quality. FDA says cagrilintide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition. FDA warns that illegally marketed GLP-1 drugs sold online may be counterfeit or contain the wrong ingredients or the wrong amount.

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: no data on cagrilintide or CagriSema in pregnancy are published. The label of semaglutide, one of the two drugs in CagriSema, says it may cause fetal harm and, for weight reduction, advises stopping it at least 2 months before a planned pregnancy because it stays in the body a long time. Breastfeeding: no data on cagrilintide in breast milk are published; the Wegovy label says breastfeeding is not recommended during treatment with Wegovy tablets.

Interactions

Insulin and sulfonylureas (such as glipizide, glyburide or glimepiride)High

Based on the label of semaglutide, which CagriSema contains (class-based, not a finding for cagrilintide itself): the Wegovy label says use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. In REIMAGINE 3, where CagriSema was added to basal insulin, no severe low blood sugar was reported.

Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide or other GLP-1 medicinesHigh

Class-based: CagriSema already contains semaglutide. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended.

Oral medicines with a narrow safety marginModerate

Based on the label of semaglutide, which CagriSema contains (class-based, not a finding for cagrilintide itself): the Wegovy label says semaglutide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to consider increased clinical or laboratory monitoring with oral medicines that have a narrow therapeutic index or need clinical monitoring. A study of how CagriSema affects warfarin and atorvastatin is listed as completed on ClinicalTrials.gov (NCT06289504), but no results are posted or published.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

The only legitimate source today is a registered clinical trial: the study is listed on ClinicalTrials.gov with an NCT number, and the study drug is supplied by the trial
In a trial you sign an informed consent form that names the sponsor, the study doctor and what is being tested
Semaglutide on its own is FDA-approved and dispensed by licensed pharmacies with a prescription; cagrilintide and CagriSema are not

Be skeptical of…

"Compounded cagrilintide" or "compounded CagriSema": FDA says cagrilintide cannot be used in compounding under federal law
"For research use only" or "not for human consumption" cagrilintide vials sold to the public: FDA says cagrilintide is not a component of any FDA-approved drug and cannot be used in compounding, so no such product has been reviewed for safety or quality
"Mix your own CagriSema" with semaglutide: no product sold this way matches what was tested, and doses were set by trial protocols
"FDA-registered" or "has an NDC number, so it is approved": FDA says assignment of an NDC number does not denote FDA approval
"Proven to protect the heart": the CagriSema heart outcomes trial has not reported
"Fewer side effects than semaglutide": stomach side effects affected about 3 in 4 people on CagriSema in the main trials

Frequently asked questions

Is CagriSema or cagrilintide FDA-approved?⌄

No. As of November 19, 2026, neither appears among FDA's approved drugs, and FDA states that cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Semaglutide, the other drug in CagriSema, is approved on its own. Only FDA can decide whether the combination is approved.

Is it legal to buy cagrilintide online?⌄

Cagrilintide is an unapproved drug, and FDA says it cannot be used in compounding under federal law. FDA urges consumers to be vigilant when buying drugs online and warns that illegally marketed GLP-1 drugs may be counterfeit or contain the wrong ingredients or amount. A registered clinical trial is the only legitimate way to receive it now.

How does CagriSema compare with semaglutide alone?⌄

In REDEFINE 5, a 68-week trial in Japan and Taiwan, average weight loss was 18.4% on CagriSema and 11.9% on semaglutide alone. In REIMAGINE 2, in type 2 diabetes, HbA1c fell slightly more with CagriSema (1.91 vs 1.75 percentage points). A head-to-head trial against tirzepatide in obesity is listed as completed on ClinicalTrials.gov (NCT06131437), but no results paper was found on PubMed as of November 19, 2026.

Can I join a CagriSema or cagrilintide trial?⌄

Trials are listed on ClinicalTrials.gov, including some still recruiting, such as a trial in children and adolescents, and a trial in high blood pressure that is listed as not yet recruiting. Each trial has its own entry rules. Your doctor can help you judge whether a trial fits you.

Can I take it with my supplements or other medicines?⌄

No interaction studies of cagrilintide with supplements have been published. Because CagriSema contains semaglutide, the semaglutide label applies: low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.

References by claim

weight loss in adults with obesity without diabetes

Garvey et al., 2025 · PubMed (2025) link

Yamauchi et al., 2026 · PubMed (2026) link

Wharton et al., 2026 · PubMed (2026) link

weight loss in adults with type 2 diabetes

Davies et al., 2025 · PubMed (2025) link

blood sugar (HbA1c) in type 2 diabetes

Buse et al., 2026 · PubMed (2026) link

Aroda et al., 2026 · PubMed (2026) link

Rosenstock et al., 2026 · PubMed (2026) link

weight loss with cagrilintide alone

Lau et al., 2021 · PubMed (2021) link

Safety

Wegovy (semaglutide) injection and tablets prescribing information · DailyMed (FDA label) link

ClinicalTrials.gov record NCT05669755 (REDEFINE 3): cardiovascular outcomes with CagriSema · ClinicalTrials.gov link

FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss · FDA link

Interaction: Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide or other GLP-1 medicines

Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link

Interaction: Oral medicines with a narrow safety margin

ClinicalTrials.gov record NCT06289504: effect of CagriSema on atorvastatin and warfarin levels · ClinicalTrials.gov link

Track Cagrilintide (CagriSema) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.